Product Pipeline

Our extended-release drug delivery technology platform allows us to develop additional drug candidates where an extended release ODT or extended release oral suspension dosage forms address unmet medical needs.

Our technology is proven to work, with FDA’s approval of two different medications for the treatment of ADHD. Beyond our initial focus on ADHD, we believe patients with central nervous system, or CNS, conditions, such as stroke, Parkinson’s Disease and Alzheimer’s Disease could benefit from an extended-release ODT or extended-release liquid suspension medication.